TY - JOUR T1 - Single-cell RNA-seq and V(D)J profiling of immune cells in COVID-19 patients JF - medRxiv DO - 10.1101/2020.05.24.20101238 SP - 2020.05.24.20101238 AU - Xiaoying Fan AU - Xiangyang Chi AU - Wenji Ma AU - Suijuan Zhong AU - Yunzhu Dong AU - Wei Zhou AU - Wenyu Ding AU - Hongyan Fan AU - Chonghai Yin AU - Zhentao Zuo AU - Yilong Yang AU - Mengyao Zhang AU - Qiang Ma AU - Jianwei Liu AU - Ting Fang AU - Qian Wu AU - Wei Chen AU - Xiaoqun Wang Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/27/2020.05.24.20101238.abstract N2 - Coronavirus disease 2019 (COVID-19) has caused over 220,000 deaths so far and is still an ongoing global health problem. However, the immunopathological changes of key types of immune cells during and after virus infection remain unclear. Here, we enriched CD3+ and CD19+ lymphocytes from peripheral blood mononuclear cells of COVID-19 patients (severe patients and recovered patients at early or late stages) and healthy people (SARS-CoV-2 negative) and revealed transcriptional profiles and changes in these lymphocytes by comprehensive single-cell transcriptome and V(D)J recombination analyses. We found that although the T lymphocytes were decreased in the blood of patients with virus infection, the remaining T cells still highly expressed inflammatory genes and persisted for a while after recovery in patients. We also observed the potential transition from effector CD8 T cells to central memory T cells in recovered patients at the late stage. Among B lymphocytes, we analyzed the expansion trajectory of a subtype of plasma cells in severe COVID-19 patients and traced the source as atypical memory B cells (AMBCs). Additional BCR and TCR analyses revealed a high level of clonal expansion in patients with severe COVID-19, especially of B lymphocytes, and the clonally expanded B cells highly expressed genes related to inflammatory responses and lymphocyte activation. V-J gene usage and clonal types of higher frequency in COVID-19 patients were also summarized. Taken together, our results provide crucial insights into the immune response against patients with severe COVID-19 and recovered patients and valuable information for the development of vaccines and therapeutic strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the special project for COVID-19 of Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2020GZR110106009), National Basic Research Program of China (2019YFA0110100).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe scRNA-seq data and V(D)J sequencing data used in this study have been deposited in the GSA. ER -